Rather than injecting antibodies, another EGFR-targeting approach undergoing investigation in pancreatic cancer collects autologous lymphocytes and expands them in vitro in the presence of OKT3 (anti-CD3) and cetuximab (anti-EGFR) in order to generate bispecific antibody armed T cells (BATs), which are then infused. This evidence concerns the gene EGFR and familial pancreatic carcinoma.